Clinical trials
Every registered trial of Relaxin-2 (Serelaxin)
16 studies.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on Relaxin-2 (Serelaxin) has been registered.
- 16 registered studies in total.
- None are currently enrolling — this research has already happened.
What kind of research
- 16 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 10,978 people took part in those.
How far along it is
- 3 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 9 have published results in the medical literature that anyone can read.
- The research spans 54 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 16 of 16 trials for Relaxin-2 (Serelaxin).
Serelaxin To Lower Portal Pressure
University of Edinburgh
Liver Cirrhosis · Hypertension, Portal
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
Novartis Pharmaceuticals
Chronic Heart Failure
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Novartis Pharmaceuticals
Acute Heart Failure
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
Novartis Pharmaceuticals
Chronic Heart Failure
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
Novartis Pharmaceuticals
Acute Heart Failure
Study of the Vascular Effects of Serelaxin
Novartis Pharmaceuticals
Coronary Artery Disease
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
Novartis Pharmaceuticals
Acute Heart Failure (AHF)
Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients
Novartis Pharmaceuticals
Acute Heart Failure
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
Novartis Pharmaceuticals
Acute Heart Failure
PK of Serelaxin in Severe Renal Impairment and ESRD
Novartis Pharmaceuticals
Renal Failure, Chronic · End-Stage Renal Disease
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
Novartis Pharmaceuticals
Pre-eclampsia
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
Novartis Pharmaceuticals
Compensated Cirrhosis and Portal Hypertension
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
Novartis Pharmaceuticals
Acute Heart Failure
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
Novartis Pharmaceuticals
Chronic Heart Failure (CHF)
Recombinant Human Relaxin for the Treatment of Decompensated CHF
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Congestive Heart Failure (CHF)
Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Labor, Induced
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Relaxin-2 (Serelaxin) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.